(Total Views: 540)
Posted On: 05/13/2025 4:07:52 PM
Post# of 154899
More inhibitor success in BRCA breast cancer.
https://www.icr.ac.uk/about-us/icr-news/detai...ast-cancer
Excerpt: OlympiA trial researchers studied 1,836 women with HER-2 negative breast cancer, who also had a mutation in their BRCA1 or BRCA2 genes and had undergone standard treatment, including surgery and chemotherapy. Patients were randomly allocated to receive either 300mg twice a day of olaparib or a placebo drug for one year.
The trial has led to NICE recommendation
Earlier results from the OlympiA trial led to the recommendation by NICE to grant people in England and Wales with early-stage, high-risk breast cancer and inherited mutations in BRCA1 or BRCA2 access to olaparib following standard treatment – helping prevent their cancer returning and improving their chances of survival.
After six years, 87.5 per cent of patients who were treated with the drug were still alive compared with 83.2 per cent of those who were given the placebo pills.
The Institute of Cancer Research, London, and King’s College London is the global lead investigator and Chair of the Steering Committee for the OlympiA study, and was also involved in early laboratory research on PARP inhibitors ..."
https://www.icr.ac.uk/about-us/icr-news/detai...ast-cancer
Excerpt: OlympiA trial researchers studied 1,836 women with HER-2 negative breast cancer, who also had a mutation in their BRCA1 or BRCA2 genes and had undergone standard treatment, including surgery and chemotherapy. Patients were randomly allocated to receive either 300mg twice a day of olaparib or a placebo drug for one year.
The trial has led to NICE recommendation
Earlier results from the OlympiA trial led to the recommendation by NICE to grant people in England and Wales with early-stage, high-risk breast cancer and inherited mutations in BRCA1 or BRCA2 access to olaparib following standard treatment – helping prevent their cancer returning and improving their chances of survival.
After six years, 87.5 per cent of patients who were treated with the drug were still alive compared with 83.2 per cent of those who were given the placebo pills.
The Institute of Cancer Research, London, and King’s College London is the global lead investigator and Chair of the Steering Committee for the OlympiA study, and was also involved in early laboratory research on PARP inhibitors ..."
(2)
(0)
